Remdesivir by Gilead, which is being developed as an Ebola treatment, is expected to benefit significantly from the spread of COVID-19.

The explosive demand for therapeutics around the world has led to unintended recruitment of clinical trials, which has resulted in significant time and cost savings. In some cases, the possibility of quick permits is also increasing.

Clinical trials in the US, China, etc, Skip Prior Authorization

The National Institute of Allergy and Infectious Diseases (NIAID) announced on the 12th that it will begin a clinical trial of Remdesivir with COVID-19.

Remdesivir is a drug that Gilead Science is developing for the Ebola virus